Read BearMO's blog in RSS
September 9, 2010
Edited: September 9, 2010
Share This
(EXAS) is a company focused on the early detection and prevention of colon cancer. It has exclusive property protecting its non-invasive screening technology. It's focus is on the commercial development and seeking FDA clearance and approval of its stool-based (DNA) colorectal cancer screening product. By detecting pre-cancers and cancers early, affected patients can be referred to colonoscopy, during which the polyp or lesion can be removed.
Colorectal cancer (commonly known as colon cancer) is the second leading cause of cancer deaths in the United States. It is estimated that roughly one-third of colorectal cancer-related deaths could be avoided if more people underwent regular screening.
EXAS estimated that even only a 30% of the screening market will reflect $1.2 Billion dollars annually. Currently the market cap for EXAS is only $144M
EXAS is targeting their data release date of clinically trial data on Oct 29, 2010.
EXAS is currently held and in our 'game' stock portfolio.
EXEL
EXEL is a biotech stock which is working on a thyroid cancer drug. It was added to the portfolio on Aug 27 influenced by insider buying. The insider buying has continued onward into Septemeber, the latest noted on Sept 3 and 7th.
EXEL is up 4% today. Smells like something good is happening to the company. A number of insider buyings has occured since Aug 13. No insider has sold since that time.
